Cargando…
Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease
Despite several recent advances in therapy in inflammatory bowel disease (IBD), 5-aminosalicylic acid (5-ASA) therapy has retained its place especially in ulcerative colitis. This consensus on 5-ASA is obtained through a modified Delphi process, and includes guiding statements and recommendations ba...
Autores principales: | Sood, Ajit, Ahuja, Vineet, Midha, Vandana, Sinha, Saroj Kant, Pai, C. Ganesh, Kedia, Saurabh, Mehta, Varun, Bopanna, Sawan, Abraham, Philip, Banerjee, Rupa, Bhatia, Shobna, Chakravartty, Karmabir, Dadhich, Sunil, Desai, Devendra, Dwivedi, Manisha, Goswami, Bhabhadev, Kaur, Kirandeep, Khosla, Rajeev, Kumar, Ajay, Mahajan, Ramit, Misra, S. P., Peddi, Kiran, Singh, Shivaram Prasad, Singh, Arshdeep |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Association for the Study of Intestinal Diseases
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7609395/ https://www.ncbi.nlm.nih.gov/pubmed/32646198 http://dx.doi.org/10.5217/ir.2019.09176 |
Ejemplares similares
-
Colitis and Crohn’s Foundation (India): a first nationwide inflammatory bowel disease registry
por: Sood, Ajit, et al.
Publicado: (2021) -
Maintaining infliximab induced clinical remission with azathioprine and 5-aminosalicylates in acute severe steroid-refractory ulcerative colitis has lower cost and high efficacy (MIRACLE): a multicenter study
por: Mahajan, Ramit, et al.
Publicado: (2022) -
Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis
por: Midha, Vandana, et al.
Publicado: (2018) -
Trends of inflammatory bowel disease at a tertiary care center in northern India
por: Sood, Ajit, et al.
Publicado: (2021) -
Exclusive enteral nutrition for induction of remission in anti-tumor necrosis factor refractory adult Crohn’s disease: the Indian experience
por: Sood, Ajit, et al.
Publicado: (2020)